Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI).

Alexander C BrantonCatherine H VuVeena VenugopalanBarbara A SantevecchiKartikeya CherabuddiReuben RamphalTanvi ManoharKathryn E Desear

Published in: JAC-antimicrobial resistance (2023)

When compared with CBPs, cefepime and piperacillin/tazobactam resulted in similar clinical cure, in-hospital mortality, recurrence and resistance emergence in the treatment of ESBL-E UTI.

Keyphrases

urinary tract infection
escherichia coli
klebsiella pneumoniae
gram negative
multidrug resistant